Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H Financial Overview
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H's market cap is currently HK$17.56B. The company's EPS TTM is HK$0.098; its P/E ratio is 16.80; and it has a dividend yield of 5.23%. Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H is scheduled to report earnings on October 30, 2025, and the estimated EPS forecast is HK$0.07. See an overview of income statement, balance sheet, and cash flow financials.
